The U.S. viscosupplementation market is witnessing significant growth, driven by rising awareness of osteoarthritis (OA) and a growing demand for minimally invasive joint treatments. Viscosupplementation, primarily involving intra-articular injections of hyaluronic acid (HA), aims to restore the viscoelastic properties of synovial fluid in affected joints, thereby reducing pain, improving mobility, and delaying the need for surgical intervention. The treatment has become increasingly popular due to its minimally invasive nature, suitability for outpatient care, and ability to address symptoms in patients who may not yet require total joint replacement.
Market statistics indicate that the U.S. viscosupplementation market is likely to be valued at approximately US$1,127.6 million in 2025, with projections estimating growth to US$1,611.7 million by 2032, reflecting a compound annual growth rate (CAGR) of 5.2% during the forecast period. This growth is underpinned by demographic trends, including an aging population and rising obesity rates, which collectively contribute to the increasing prevalence of OA. Knee osteoarthritis remains the most dominant application segment due to its high incidence among adults aged 55 and above, while single injection HA formulations are preferred for their convenience and patient compliance. Geographically, the U.S. remains the leading region for viscosupplementation adoption because of well-established healthcare infrastructure, strong reimbursement policies, and high patient awareness.
Download Your Free Sample & Explore Key Insights: https://www.persistencemarketresearch.com/samples/35654
Key Highlights from the Report
• The U.S. viscosupplementation market is projected to reach US$1,611.7 million by 2032.
• Single injection formulations dominate the product segment due to convenience and adherence.
• Knee osteoarthritis remains the primary application for viscosupplementation procedures.
• Technological advancements in HA formulations are driving therapeutic expansion.
• Combination therapies with HA and regenerative or anti-inflammatory agents present innovation opportunities.
• Outpatient and ambulatory care adoption is supporting market growth and accessibility.
Market Segmentation
The U.S. viscosupplementation market is segmented primarily based on product type and application. By product type, single injection HA formulations lead due to the reduced number of clinic visits required, higher patient compliance, and minimized discomfort compared to multi-injection regimens. These formulations have been further enhanced through technological advancements such as cross-linking and longer-lasting HA variants, allowing for extended therapeutic effects and better outcomes. Multi-injection viscosupplementation remains a secondary segment, typically prescribed when extended or repeat therapy is necessary, though it is less preferred due to patient inconvenience.
By application, knee osteoarthritis is the leading segment within the U.S., given the high prevalence of knee joint degeneration among the adult population. Other applications include hip, shoulder, and ankle OA treatments, though these account for a smaller market share. Knee OA remains a focal point for clinical adoption due to its impact on mobility and quality of life, making HA injections an attractive, minimally invasive alternative to surgical procedures. The market is also categorized by end-user, with outpatient clinics and ambulatory care centers emerging as primary treatment venues due to the ease and safety of HA injections in non-hospital settings.
Regional Insights
Regionally, the U.S. represents the most significant market for viscosupplementation globally, driven by advanced healthcare infrastructure, favorable reimbursement policies, and a high prevalence of osteoarthritis. Urban centers and states with larger elderly populations, such as Florida, Texas, and California, show particularly high adoption rates. Increasing awareness campaigns by healthcare providers and collaborations with orthopedic clinics have further enhanced patient access. Moreover, the integration of outpatient and ambulatory care settings as preferred treatment locations has strengthened regional adoption, allowing patients to access effective pain management solutions without requiring hospitalization. Research initiatives focusing on combination therapies with regenerative agents and advanced HA formulations are also more concentrated in the U.S., providing a competitive advantage and fostering continuous innovation.
Get Custom Insights Designed for Your Business: https://www.persistencemarketresearch.com/request-customization/35654
Market Drivers
The primary drivers of growth in the U.S. viscosupplementation market include the increasing prevalence of osteoarthritis, aging population demographics, and rising demand for minimally invasive therapies. Osteoarthritis affects approximately 32.5 million adults in the U.S., with nearly half of those with symptomatic knee OA under 65 years old. Lifestyle factors such as obesity, sedentary habits, and joint injuries further exacerbate the incidence of OA. Viscosupplementation injections offer a targeted, non-surgical treatment solution that addresses pain, stiffness, and reduced mobility. Additionally, technological advancements in HA formulations, including crosslinked and longer-acting variants, have improved therapeutic efficacy, encouraging adoption by physicians and patients. The growing preference for outpatient and ambulatory care treatments further supports market expansion, providing convenient and cost-effective options for OA management.
Market Restraints
Despite strong growth potential, the U.S. viscosupplementation market faces several challenges. Availability of alternative treatments, such as corticosteroid injections, physical therapy, and emerging procedures like genicular artery embolization (GAE), can limit widespread adoption of HA injections. These alternatives are often perceived as more cost-effective and familiar within clinical practice, particularly in healthcare systems where reimbursement for viscosupplementation may be limited. Additionally, some patients may prefer established therapies due to their proven safety profiles and lower initial costs. Regulatory hurdles and variability in insurance coverage can also act as barriers, restricting access and adoption in certain patient populations. Such factors collectively temper the market growth despite increasing OA prevalence.
Market Opportunities
The U.S. viscosupplementation market offers significant opportunities for innovation and expansion. Combination therapies integrating HA with regenerative agents such as platelet-rich plasma (PRP) or anti-inflammatory drugs are emerging as high-potential treatment options, providing synergistic effects that enhance cartilage repair and reduce inflammation. Advancements in biomaterials, including natural polymers like chitosan and alginate, as well as synthetic polymers such as polylactic-co-glycolic acid, are being explored for drug delivery and tissue-engineering applications. Crosslinked HA formulations and longer-acting variants also offer extended therapeutic benefits, enhancing patient convenience and adherence. Moreover, partnerships with outpatient clinics and ambulatory care networks provide avenues to strengthen market penetration and establish HA injections as a preferred standard of care for OA management.
Checkout Now & Download Complete Market Report: https://www.persistencemarketresearch.com/checkout/35654
Company Insights
Key players operating in the U.S. viscosupplementation market include:
• Sanofi S.A.
• Zimmer Biomet Holdings Inc.
• Bioventus LLC
• Anika Therapeutics Inc.
• Fidia Pharma USA Inc.
• Ferring B.V.
• Seikagaku Corporation
• OrthogenRx Inc. (Channel-Markers Medical)
• Medical Device Business Services, Inc. (J&J)
• AVNS
• Searchlight Pharma Inc.
• Aptissen GmbH
• Teva Pharmaceutical Industries Ltd.
• TRB Chemedica International SA
• IBSA Institut Biochimique SA
Recent developments in the market include Seikagaku Corporation collaborating with Ono Pharmaceutical Co., Ltd. in April 2025 to co-develop and market the Gel-One intra-articular injection using cross-linking technology. Additionally, in April 2024, BioSenic reported positive Phase 3 study results for its single injection product JTA-004, demonstrating safety and efficacy in the treatment of knee osteoarthritis.
Conclusion
The U.S. viscosupplementation market is positioned for steady growth, supported by the rising prevalence of osteoarthritis, technological advancements in HA formulations, and increasing demand for minimally invasive treatments in outpatient settings. Single injection therapies and knee OA applications remain the dominant segments, driven by patient convenience and clinical effectiveness. While competition from alternative therapies and reimbursement challenges present certain restraints, opportunities in combination therapies, biomaterial innovations, and strategic partnerships provide avenues for continued market expansion. With a robust pipeline of product development and strong regional adoption, the U.S. viscosupplementation market is expected to maintain its leadership position globally, offering effective solutions to improve patient quality of life and reduce the overall burden of osteoarthritis on the healthcare system.
